Impact of Phase 2b Strategies on Optimization of Drug Development Programs

Zoran Antonijevic (), Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Chris Jennison, Martin Kimber, Olga Marchenko, Nitin R. Patel and José Pinheiro
Additional contact information
Zoran Antonijevic: Cytel Inc.
Jim Bolognese: Cytel Inc.
Carl-Fredrik Burman: AstraZeneca R&D
Christy Chuang-Stein: Pfizer
Chris Jennison: University of Bath
Martin Kimber: Tessella
Olga Marchenko: Quintiles Innovation
Nitin R. Patel: Cytel Inc.
José Pinheiro: Janssen R&D

Chapter Chapter 6 in Optimization of Pharmaceutical R&D Programs and Portfolios, 2015, pp 83-103 from Springer

Abstract: Abstract Selecting the right dose is critical for the success of any drug development program, and for maximizing the value of a product. A well selected dose will have a better chance to demonstrate a desirable risk/benefit profile and thus increase the chance of regulatory success and reimbursement by payors. It will also result in improved patient care and greater benefit to society. Multiple papers have been published within industry’s adaptive design working groups, and these are the key findings. Given that dose selection impacts Phase 3 parameters, it should be assessed in a broader context of the whole development program. There isn’t one solution for all possible development scenarios. For every situation one should specify a series of alternative program scenarios and compare them. Study design has a great impact on the value of a product. Dose selection criteria must be consistent with ultimate program objectives. Additionally, targeting the minimum effective dose should be avoided. Adaptive designs perform much better than fixed designs in dose-selection studies. Larger dose-finding studies improve the chance to select the optimal dose, but this should be balanced against higher costs, and longer development time.

Keywords: Dose selection criteria; Value of selected dose; Development scenarios; Program level optimization; Adaptive design; Simulations (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-09075-7_6

Ordering information: This item can be ordered from
http://www.springer.com/9783319090757

DOI: 10.1007/978-3-319-09075-7_6

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().